Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Feb 16, 2022 8:37am
144 Views
Post# 34432985

RE:Trog IV push data

RE:Trog IV push dataTwo days, two press releases after two months with no press releases. Maybe they are learning finally how to build some momentum and anticipation among investors.

This is old news but the new information is the PDUFA date of 10/3. It looks like Bloomberg had the early Februray date wrong and got the acceptence of their application by the FDA mixed up withthe PDUFA date. 

I think it should be mentioned that the IV Push version will be approved about 4 and a half years after the original version of Trogarzo when Taimed and TH were saying at the time of the first approval they would have a new version of Trogarzo ready to go about a year after the initial approval. Clearly, there were issues in developing this version that were not anticipated originally but Taiimed likely gets the blame for that. 

I suspect the new version will help sales a little but the biggest issue now for Trogarzo is competition. Had they been able to develop this better version of the drug in a more timely fashion, it may have helped them lock up more patients before the competition arrived,  



<< Previous
Bullboard Posts
Next >>